The landscape of obesity management shifted dramatically in early 2026 as oral GLP-1 receptor agonist pills gained FDA approval and began reaching patients across the United States. These convenient daily tablets offer a needle-free alternative to popular injectable treatments like Wegovy and Zepbound, promising significant weight loss while addressing...